Novartis’ Sandoz said that it will appeal the ruling of a US district court pertaining to the patent infringement case on Erelzi (etanercept-szzs), the company’s biosimilar to Amgen’s Enbrel (etanercept).
12 Aug 2019
20 Mar 2019
A settlement between Novo Nordisk and Teva Pharmaceuticals USA (Teva) has been reached on the US patent litigation case for Victoza (liraglutide).
20 Feb 2019
Innovation Pharmaceuticals said that the US Patent & Trademark Office has issued a new patent to the company for the treatment of oral mucositis.
11 Jan 2019
03 Jan 2019
Ironwood Pharmaceuticals and Allergan have reached an agreement with Mylan Pharmaceuticals to resolve patent litigations over Mylan’s abbreviated new drug applications (ANDAs) seeking approval to market generic versions of LINZESS (linaclotide) before the expiration of their applicable patents.
11 Dec 2018
RNAi therapeutics firm Alnylam Pharmaceuticals has entered into a settlement and license agreement with Silence Therapeutics, a biotechnology company that develops gene therapeutic technology based on RNA interference.
29 Nov 2018
Vor Biopharma secures US patent covering compositions and methods to treat haematologic malignancies
The US Patent and Trademark Office (USPTO) issued US Patent No. 10,137,155 related to Vor Biopharma's technology platform.
21 Nov 2018
Dr. Reddy’s Laboratories said that the US Court of Appeals for the Federal Circuit issued a decision in its favor by concluding that Indivior had not shown that it is likely to succeed on the merits of its infringement case on US Patent No. 9,931,305.
29 Aug 2018
Assertio Therapeutics has reached a settlement with Purdue Pharma over a patent infringement lawsuit it filed against the latter related to its commercialization of Oxycontin (oxycodone hydrochloride-controlled release).
27 Oct 2017
The UK High Court of Justice has given a decision in favor of Mylan and Synthon over their dispute concerning the patent of Teva Phamaceutical Industries’ multiple sclerosis (MS) treatment Copaxone which was ruled to be invalid due to obviousness.